Erratum to “Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study”

In the article titled “Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study” [1], “IGT N = 2” in the Post SSA column in Figure 1 was incorrect due to a production error and should be “IGT N = 12”. The updated Figure 1 is as follows:

1Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China
2Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai 200040, China
3Department of Endocrinology and Metabolism, The Second People’s Hospital of Kashi, Xinjiang Uygur Autonomous Region 844000, China
4Department of Nuclear Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China

Correspondence should be addressed to Meng Wang; wm20134233004@126.com

Received 26 November 2018; Accepted 13 December 2018; Published 10 March 2019

Copyright © 2019 Ming Shen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Figure 1: Flowchart of prevalence of NGT, IGT, and DM at pretreatment and after SSA treatment, and the change of glucose metabolism status after SSA therapy. NGT: normal glucose tolerance; IGT: impaired glucose tolerance; DM: diabetes mellitus.

References
